Nuvectis Pharma (NVCT) Operating Income (2021 - 2026)

Nuvectis Pharma has reported Operating Income for 6 years, with the latest figure at -$6.3 million in Q1 2026.

• Quarterly Operating Income fell 12.43% year-over-year to -$6.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$28.3 million (down 34.48% YoY) and the FY2025 annual result came in at -$27.6 million, down 38.93% from the prior year.
• Operating Income climbed to -$6.3 million in Q1 2026 per NVCT's latest filing, from -$7.6 million in the prior quarter.
• Over five years, Operating Income peaked at -$2.9 million in Q1 2022 and troughed at -$7.8 million in Q3 2025.
• A 5-year average of -$5.6 million and a median of -$5.9 million in 2022 frame the typical range for Operating Income.
• The widest YoY moves for Operating Income: up 39.83% in 2022, down 199.25% in 2022.
• Over 5 years, Operating Income stood at -$6.8 million in 2022, then fell by 1.3% to -$6.9 million in 2023, then advanced by 6.07% to -$6.4 million in 2024, then dropped by 18.11% to -$7.6 million in 2025, then rose by 17.82% to -$6.3 million in 2026.
• According to Business Quant data, Operating Income over the past three periods registered -$6.3 million, -$7.6 million, and -$7.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.